Moreover, pembrolizumab was recently approved by the United States FDA in combination with chemotherapy (nab-paclitaxel, paclitaxel, or gemcitabine/carboplatin) for advanced PD-L1-positive triple negative breast cancer (TNBC), after a progression-free survival advantage was observed in a large randomized phase 3 study.7 Here, CD274 is linked to triple-negative breast carcinoma.